MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, announces that it has completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”). As part of the transaction, SKNY fulfilled all closing obligations, contributing $5 million in marketable securities to MIRA, further strengthening the Company’s balance sheet. “The successful closing of the SKNY acquisition marks a pivotal milestone for MIRA, both financially and strategically,” said Erez Aminov, CEO of MIRA.
Read the full article: MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-closes-acquisition-of-skny-pharmaceuticals-expan-1079783